MAZZEO, ROBERTA
MAZZEO, ROBERTA
DMED - DIPARTIMENTO DI MEDICINA
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects
2022-01-01 Di Nardo, P.; Lisanti, C.; Garutti, M.; Buriolla, S.; Alberti, M.; Mazzeo, R.; Puglisi, F.
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva
2020-01-01 Bartoletti, M.; Mazzeo, R.; De Scordilli, M.; Del Fabro, A.; Vitale, M. G.; Bortot, L.; Nicoloso, M. S.; Corsetti, S.; Bonotto, M.; Scalone, S.; Giorda, G.; Sorio, R.; Andreetta, C.; Meacci, M. L.; De Vivo, R.; Fasola, G.; Sopracordevole, F.; Puglisi, F.
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
2024-01-01 Bartoletti, M.; Montico, M.; Lorusso, D.; Mazzeo, R.; Oaknin, A.; Musacchio, L.; Scambia, G.; Puglisi, F.; Pignata, S.
The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era
2024-01-01 Garcia-Illescas, D.; Mazzeo, R.; Garcia-Duran, C.; Oaknin, A.
The Impact of Cereal Grain Composition on the Health and Disease Outcomes
2022-01-01 Garutti, Mattia; Nevola, Gerardo; Mazzeo, Roberta; Cucciniello, Linda; Totaro, Fabiana; Alejandro Bertuzzi, Carlos; Caccialanza, Riccardo; Pedrazzoli, Paolo; Puglisi, Fabio
“Intestinal-Type” Vulvar Adenocarcinoma: A Review of the MITO Rare Tumors Group
2022-01-01 Dellino, M.; Cicogna, S.; Falcone, F.; Mitidieri, M.; Mazzeo, R.; Pignata, S.; Mangili, G.; Cormio, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects | 1-gen-2022 | Di Nardo, P.; Lisanti, C.; Garutti, M.; Buriolla, S.; Alberti, M.; Mazzeo, R.; Puglisi, F. | |
| Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva | 1-gen-2020 | Bartoletti, M.; Mazzeo, R.; De Scordilli, M.; Del Fabro, A.; Vitale, M. G.; Bortot, L.; Nicoloso, M. S.; Corsetti, S.; Bonotto, M.; Scalone, S.; Giorda, G.; Sorio, R.; Andreetta, C.; Meacci, M. L.; De Vivo, R.; Fasola, G.; Sopracordevole, F.; Puglisi, F. | |
| Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis | 1-gen-2024 | Bartoletti, M.; Montico, M.; Lorusso, D.; Mazzeo, R.; Oaknin, A.; Musacchio, L.; Scambia, G.; Puglisi, F.; Pignata, S. | |
| The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era | 1-gen-2024 | Garcia-Illescas, D.; Mazzeo, R.; Garcia-Duran, C.; Oaknin, A. | |
| The Impact of Cereal Grain Composition on the Health and Disease Outcomes | 1-gen-2022 | Garutti, Mattia; Nevola, Gerardo; Mazzeo, Roberta; Cucciniello, Linda; Totaro, Fabiana; Alejandro Bertuzzi, Carlos; Caccialanza, Riccardo; Pedrazzoli, Paolo; Puglisi, Fabio | |
| “Intestinal-Type” Vulvar Adenocarcinoma: A Review of the MITO Rare Tumors Group | 1-gen-2022 | Dellino, M.; Cicogna, S.; Falcone, F.; Mitidieri, M.; Mazzeo, R.; Pignata, S.; Mangili, G.; Cormio, G. |